This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Adam Feuerstein

Senior Columnist

Before joining TheStreet in March 2001, Feuerstein covered business software for Prior to that he covered a variety of business beats, including technology and commercial real estate, at the San Francisco Business Times.

Feuerstein graduated from Emory University with a bachelor's degree in political science.

Adam Feuerstein
By This Author:
« Back
Page 1 of 568

Ampio: The Freezer Killed My Osteoarthritis Drug

By Adam Feuerstein

Ampio Pharmaceuticals is blaming a mini Polar Vortex for blowing up a pivotal study of its osteoarthritis drug Ampion.

10:23AM 08/21/14

Galena CEO Fired Following Stock-Promotions Scandal

By Adam Feuerstein

Mark Ahn's forced exit from the troubled Galena follows an internal investigation by the board.

07:16AM 08/21/14

Yes, Call It a Comeback: Amicus Fabry Drug Posts Big Study Win

By Adam Feuerstein

Based on the positive study results, Amicus intends to seek European approval for migalastat early next year.

06:01AM 08/20/14

Biotech Stock Mailbag: Exact Sciences, Galena, Amgen

By Adam Feuerstein

Biotech columnist Adam Feuerstein answers readers' questions about health care.

07:22AM 08/15/14

Northwest Bio Can't Keep Its DC-Vax Claims Straight

By Adam Feuerstein

Contradictory statements made on whether or not Northwest Bio conducted an interim analysis of its DC-Vax phase III study.

10:20AM 08/14/14

Blame MannKind's Fall on its Bloated Balance Sheet

By Adam Feuerstein

Even in biotech where the "blue sky" potential for experimental drugs so often sends stock prices soaring, no company can escape the gravitational pull of balance sheets and income statements.

12:04PM 08/13/14

Arrowhead Discloses First Human Hepatitis B Therapy Results

By Adam Feuerstein

The announcement is short on specific details but the Arrowhead drug, ARC-520, appears to have passed through its first clinical hurdle in hepatitis B patients relatively well.

05:11PM 08/12/14

Northwest Bio DC-Vax Study Changes Hint at Failure

By Adam Feuerstein

It's obvious DC-Vax came up futile in the early look at the phase III study data, leaving almost no chance the experimental cancer vaccine would benefit patients.

11:18AM 08/12/14

Dendreon Warns Debt Bomb Might Wipe Out Shareholders

By Adam Feuerstein

The struggling Provenge peddler is suffocating under $620 million in debt and the bill comes soon.

07:17AM 08/12/14

Intercept Pharma Shares Higher on Positive Fatty Liver Drug Data

By Adam Feuerstein

Intercept's OCA data look good. I don't see anything in the study results which scream, "RUN AWAY!" This is what some investors feared, causing the stock price to fall recently.

05:29PM 08/11/14

« Back
Page 1 of 568

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
DOW 17,039.49 +60.36 0.36%
S&P 500 1,992.37 +5.86 0.30%
NASDAQ 4,532.1040 +5.6220 0.12%

Brokerage Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs